Role of Hormonal Therapy for Prostate Cancer: Perspective from Japanese Experiences

Overview

Journal Transl Androl Urol

Date 2016 Jan 28

PMID 26813083

Citations 8

Authors

Mikio Namiki

Satoru Ueno

Yasuhide Kitagawa

Affiliations

Soon will be listed here.

Abstract

Hormonal therapy has been playing an important role in the treatment of prostate cancer. However, it has recently been the subject of criticism that it shows minimal effectiveness, it may reduce patients' quality of life, and induce adverse effects. On the other hand, next-generation hormonal drugs have provided new strategies for hormonal therapy to overcome advanced prostate cancer. Therefore, it is necessary to accumulate further clinical evidence concerning the efficacy and adverse effects of hormonal therapy. And, what is important for the treatment of prostate cancer is how we use hormonal therapy most effectively. This article presents a review of the possible roles of hormonal therapy for prostate cancer based upon experience in Japan.

Citing Articles

Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer.

Shin W, Han S, Jo K, Cho Y, Kim K Sci Rep. 2023; 13(1):16663.

PMID: 37794090 PMC: 10550987. DOI: 10.1038/s41598-023-43561-5.

Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy.

Shigehara K, Izumi K, Nakashima K, Kawaguchi S, Nohara T, Kadono Y Transl Androl Urol. 2021; 9(6):2533-2540.

PMID: 33457227 PMC: 7807326. DOI: 10.21037/tau-20-901.

Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.

Uemura H, Koroki Y, Iwaki Y, Imanaka K, Kambara T, Lopez-Gitlitz A BMC Urol. 2020; 20(1):139.

PMID: 32878613 PMC: 7465330. DOI: 10.1186/s12894-020-00689-0.

Increased tumor-associated macrophages in the prostate cancer microenvironment predicted patients' survival and responses to androgen deprivation therapies in Indonesian patients cohort.

Yuri P, Shigemura K, Kitagawa K, Hadibrata E, Risan M, Zulfiqqar A Prostate Int. 2020; 8(2):62-69.

PMID: 32647642 PMC: 7335973. DOI: 10.1016/j.prnil.2019.12.001.

Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.

Cheung S, Hamuro Y, Mahlich J, Nakayama M, Tsubota A PLoS One. 2018; 13(4):e0195789.

PMID: 29694373 PMC: 5919000. DOI: 10.1371/journal.pone.0195789.

References

Dorff T, Flaig T, Tangen C, Hussain M, Swanson G, Wood Jr D . Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol. 2011; 29(15):2040-5. PMC: 3107759. DOI: 10.1200/JCO.2010.32.2776. View

Scher H, Beer T, Higano C, Anand A, Taplin M, Efstathiou E . Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724):1437-46. PMC: 2948179. DOI: 10.1016/S0140-6736(10)60172-9. View

Seruga B, Ocana A, Tannock I . Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2010; 8(1):12-23. DOI: 10.1038/nrclinonc.2010.136. View

Horwitz E, Bae K, Hanks G, Porter A, Grignon D, Brereton H . Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008; 26(15):2497-504. DOI: 10.1200/JCO.2007.14.9021. View

Narimoto K, Mizokami A, Izumi K, Mihara S, Sawada K, Sugata T . Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen. Int J Urol. 2010; 17(4):337-45. DOI: 10.1111/j.1442-2042.2010.02473.x. View

Widmark A, Klepp O, Solberg A, Damber J, Angelsen A, Fransson P . Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2008; 373(9660):301-8. DOI: 10.1016/S0140-6736(08)61815-2. View

Hoffman R, Hunt W, Gilliland F, Stephenson R, Potosky A . Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer. 2003; 97(7):1653-62. DOI: 10.1002/cncr.11233. View

Akakura K, Ito H, Sato N . [Intermittent androgen suppression for prostate cancer]. Nihon Rinsho. 2000; 58 Suppl:289-91. View

Stock R, Cahlon O, Cesaretti J, Kollmeier M, Stone N . Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2004; 59(5):1352-9. DOI: 10.1016/j.ijrobp.2004.01.023. View

10.

Sun S, Sprenger C, Vessella R, Haugk K, Soriano K, Mostaghel E . Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010; 120(8):2715-30. PMC: 2912187. DOI: 10.1172/JCI41824. View

11.

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

12.

Akaza H . Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment. Pharmacology. 2010; 85(2):110-20. DOI: 10.1159/000274486. View

13.

Soifer H, Souleimanian N, Wu S, Voskresenskiy A, Collak F, Cinar B . Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem. 2011; 287(6):3777-87. PMC: 3281677. DOI: 10.1074/jbc.M111.261933. View

14.

Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K . The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res. 2004; 64(2):765-71. DOI: 10.1158/0008-5472.can-03-0130. View

15.

Stanbrough M, Bubley G, Ross K, Golub T, Rubin M, Penning T . Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006; 66(5):2815-25. DOI: 10.1158/0008-5472.CAN-05-4000. View

16.

Koh Y, Buczko E, Dufau M . Requirement of phenylalanine 343 for the preferential delta 4-lyase versus delta 5-lyase activity of rat CYP17. J Biol Chem. 1993; 268(24):18267-71. View

17.

DAmico A, Denham J, Crook J, Chen M, Goldhaber S, Lamb D . Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007; 25(17):2420-5. DOI: 10.1200/JCO.2006.09.3369. View

18.

Izumi K, Mizokami A, Sugimoto K, Narimoto K, Miwa S, Maeda Y . Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology. 2009; 73(6):1342-6. DOI: 10.1016/j.urology.2009.01.046. View

19.

Yamashita S, Lai K, Chuang K, Xu D, Miyamoto H, Tochigi T . ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia. 2012; 14(1):74-83. PMC: 3281944. DOI: 10.1593/neo.111436. View

20.

Nag S, Beyer D, Friedland J, Grimm P, Nath R . American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 1999; 44(4):789-99. DOI: 10.1016/s0360-3016(99)00069-3. View